TSXV - Delayed Quote CAD
Quest PharmaTech Inc. (QPT.V)
0.0350
-0.0100
(-22.22%)
At close: May 9 at 11:59:46 AM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ragupathy Madiyalakan Ph.D. | CEO & Director | 250k | -- | -- |
| Mr. Pierre Vermette C.A., CPA | Chief Financial Officer | 74.17k | -- | -- |
| Mr. Roger Andrews | Head of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Douglas C. Bachman | Vice President of Corporate Development | 37.94k | -- | 1954 |
| Mr. Thomas Woo | Vice President of Product Development | -- | -- | -- |
Quest PharmaTech Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer. It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is headquartered in Edmonton, Canada.
Corporate Governance
Quest PharmaTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 27, 2025 at 8:00 PM UTC - June 2, 2025 at 8:00 PM UTC
Quest PharmaTech Inc. Earnings Date
Recent Events
July 21, 2005 at 12:00 AM UTC
Ex-Dividend Date